Heading into the clinic
STRASBOURG, France—Last month saw biotech company Transgene announce plans to move its lead candidate, TG4050, into clinical development and to finalize its collaboration with NEC. Transgene will assume responsibility for TG4050’s clinical development and will launch two clinical trials in H2 2019 to evaluate the candidate’s safety and immunogenicity: one in patients with ovarian cancer who have undergone first-line surgery and chemotherapy, and one in patients with head and neck cancer who have undergone surgery and radiation therapy. Transgene and NEC will co-finance the studies. TG4050 is an individualized immunotherapy designed and manufactured with Transgene’s proprietary myvac platform and integrates neoantigens chosen by NEC’s Neoantigen Prediction System.